{
  "docId": "019de071-d756-7568-8588-410684bab010",
  "docSlug": "c18c99fc10f671fc397f8a743cdc0ce4",
  "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 23 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 23,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a three-part structure to summarize clinical trial outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-d756-7568-8588-410684bab010/15",
  "deckHref": "/decks/019de071-d756-7568-8588-410684bab010",
  "deckJsonHref": "/decks/019de071-d756-7568-8588-410684bab010.json",
  "deckAnchorHref": "/decks/019de071-d756-7568-8588-410684bab010#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Lowering Plasma Arginine Accompanied by Improvement in Mobility. Pivotal Data Supports Planned BLA Submission in First Half of 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90664889-5982-4725-ac67-d72ae64731eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.88,
        "x": 0.06,
        "y": 0.4
      },
      "kind": "list",
      "text": "Impact on Mobility: GMFM-E mean score improved by 4.2 units (pegzilarginase) vs 0.4 units (placebo); difference of 4.6 units (p=0.1087).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bba34ad5-ae04-4c99-9cf0-404bdbd58d3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.88,
        "x": 0.06,
        "y": 0.0015
      },
      "kind": "list",
      "text": "Substantial Reduction in Plasma Arginine: 80% reduction at 24-weeks (p<0.0001); 90.5% achieved normal levels (p<0.0001).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be47532c-da86-427a-aa4f-dece3c8cd0ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.6
      },
      "kind": "list",
      "text": "Favorable Safety Profile: Consistent with previous trials; no treatment discontinuations due to adverse events.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1ee9773-a7db-47db-b595-a75c02ed94b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.22,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "GMFM-E = Gross Motor Function Measure Part E...; ARG1-D = Arginase 1 Deficiency; ‡geometric mean; *nominal p value",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31818d40-f750-4cf9-9db4-361a6ca2b370",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.88,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "First Potential Therapy to Normalize Plasma Arginine Levels in ARG1-D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ca5f39d-fd1f-4ff1-94d7-0e2bf540e33a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "81d36eb9-c56a-4571-9f51-feb9c7f6295f",
      "evidence": "Presents Pegzilarginase's benefits in managing arginine levels and improving patient outcomes.",
      "position": 1,
      "objective": "Demonstrates how Pegzilarginase meets the need for effective arginine reduction",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}